comparemela.com

Latest Breaking News On - Ken takanashi - Page 1 : comparemela.com

Satsuma Pharmaceuticals : Termination of Material Agreement - Form 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 . | June 8, 2023

Japan
Washington
United-states
Delaware
State-of-delaware
American
Nippon
Japanese
Thomasb-king
Tom-soloway
Shinji-nitanda
Mutya-harsch

Form 8-K Satsuma Pharmaceuticals, For: Jun 06

Form 8-K Satsuma Pharmaceuticals, For: Jun 06
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Delaware
United-states
State-of-delaware
Japan
Washington
American
Japanese
Nippon
Shunji-haruta
Heath-lukatch
Shuichi-kanazashi
Michael-riebe

Ken Takanashi Purchases 22,053,581 Shares of Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Stock

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) Director Ken Takanashi purchased 22,053,581 shares of the business’s stock in a transaction that occurred on Tuesday, June 6th. The stock was bought at an average price of $0.91 per share, for a total transaction of $20,068,758.71. Following the purchase, the director now directly owns 24,847,694 shares in […]

United-states
America
Ken-takanashi
News-ratings-for-satsuma-pharmaceuticals-daily
Satsuma-pharmaceuticals
Nasdaq
America-corp
Institutional-trading-of-satsuma-pharmaceuticals
Satsuma-pharmaceuticals-stock-performance
Investment-advisers
Satsuma-pharmaceuticals-inc
Millennium-management

New York Mortgage Trust, Inc. (NASDAQ:NYMTN) Declares Quarterly Dividend of $0.50

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) Director Ken Takanashi acquired 22,053,581 shares of Satsuma Pharmaceuticals stock in a transaction dated Tuesday, June 6th. The shares were purchased at an average price of $0.91 per share, with a total value of $20,068,758.71. Following the acquisition, the director now owns 24,847,694 shares of the company’s stock, […]

Ken-takanashi
Satsuma-pharmaceuticals-stock-performance
Nasdaq
Institutional-investors-weigh-in-on-satsuma-pharmaceuticals
Satsuma-pharmaceuticals
Satsuma-pharmaceuticals-company-profile
Capital-management
Vanguard-group-inc
Walleye-capital
Satsuma-pharmaceuticals-inc
Renaissance-technologies
News-ratings-for-satsuma-pharmaceuticals-daily

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.